Nonspecific Ulcerative Colitis in Practice of Family Doctor
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Ивашкин В.Т. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации колопроктологов России по диагностике и лечению язвенного колита / Ивашкин В.Т., Шептулин А.А., Шифрин О.С. и др. – 2017. PDF
Ивашкин В.Т., Шептулин А.А., Шифрин О.С., Галимова С.Ф., Юрманова Е.Н. Микроскопический колит: клинические формы, диагностика, лечение / Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2006. – Т. 16, № 6. – С. 56–60.
Корнеева О.И., Ивашкин В.Т. Антибиотикоассоциированный колит: патоморфология, клиника, лечение / Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2007. – Т. 17, № 3. – С. 65–71.
Наказ Міністерства охорони здоров’я України від 11.02.2016 № 90: Уніфікований клінічний протокол медичної допомоги (УКПМД) при запальних захворюваннях кишечника (хвороба Крона, виразковий коліт). PDF
Annese V, Daperno M, Rutter MD, et al. European Crohn’s and Colitis Organisation. European evidence-based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013;7:982–1018. https://doi.org/10.1016/j.crohns.2013.09.016
Clinical and endoscopic scoring systems in inflammatory bowel disease / Statement 4.1. ECCO-ESGAR Diagnostics GL [2018].
Costa F., Mumolo M.G., Bellini M., Romano M.R., Ceccarelli L., Arpe P. et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver. Dis. – 2003; 35:642–7. https://doi.org/10.1016/S1590-8658(03)00381-5
Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged ≥18 years – United States, 2015. MMWR Morb Mortal Wkly Rep. 2016; 65(42):1166–1169. https://doi.org/10.15585/mmwr.mm6542a3
Dignass A. et al. Second EUROPEAN evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management, Journal of Crohn’s and Colitis. – 2012. https://doi.org/10.1016/j.crohns.2012.09.002
Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56:1394–403. https://doi.org/10.1136/gut.2006.108043
http://www.gastro.ru/userfiles/R_YaK_2015_1.pdf
Magro F, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extraintestinal manifestations, pregnancy, cancer surveillance, surgery, and ileoanal pouch disorders. J Crohns Colitis 2017; 11:649–70. https://doi.org/10.1093/ecco-jcc/jjx008
Mindenmark M., Larsson A. Rulling out IBD estimation of the possible economic effects of preendoscopic screening with F-calprotectin. Clin. Biochem. – 2012; 45: 552–5. https://doi.org/10.1016/j.clinbiochem.2011.10.015
Nguyen GC, Chong CA, Chong RY. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohns Colitis. 2014; 8:288–295. https://doi.org/10.1016/j.crohns.2013.09.001
Vinding KK, Elsberg H, Thorkilgaard T, et al. Fecal calprotectin measured by patients at home using smartphones – new clinical tool in monitoring patients with inflammatory bowel disease. Inflamm Bowel Dis 2016; 22:336–44. https://doi.org/10.1097/MIB.0000000000000619
